Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial

Group 1 - Absci Corporation (NASDAQ:ABSI) has initiated the Phase 1/2a HEADLINE clinical trial for ABS-201, an experimental anti-prolactin receptor antibody, with the first healthy volunteers dosed [2] - The trial aims to evaluate effectiveness, pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability, with interim results expected in late 2026 [2] - ABS-201 targets indications in women's health and dermatology, representing a strategic move to advance internally produced assets into clinical development [2] Group 2 - Following an investor event, H.C. Wainwright raised its price target for Absci Corporation from $7 to $8 while maintaining a Buy rating, incorporating ABS-201 into its financial model [3] - The firm highlighted the potential of ABS-201 to increase the percentage of hair follicles in the growth phase, which is crucial for addressing hair loss [3] - The preclinical evidence presented during the event was noted to lend credibility to the ABS-201 program [3] Group 3 - Absci Corporation is recognized as an artificial intelligence-powered synthetic biology firm focused on unlocking the potential of proteins as the next generation of drugs [4] - While the potential of ABSI as an investment is acknowledged, there are opinions that other AI stocks may offer greater upside potential with less downside risk [4]